Anzeige
Mehr »
Login
Samstag, 13.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
X-Leak: Jetzt der Mega-Meilenstein - Kurseskalation vorprogrammiert?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QHQ0 | ISIN: US92731L1061 | Ticker-Symbol:
NASDAQ
12.04.24
21:57 Uhr
0,961 US-Dollar
-0,040
-3,95 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
VINCERX PHARMA INC Chart 1 Jahr
5-Tage-Chart
VINCERX PHARMA INC 5-Tage-Chart

Aktuelle News zur VINCERX PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiVincerx (VINC) Tumbles on Results From Cancer Therapy Study4
DiWhy Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday?3
DiWhy Is Vincerx Pharma (VINC) Stock Down 64% Today?3
DiVincerx in selloff after early-stage data for cancer therapy6
DiVincerx Pharma tumbles as cancer therapy study data comes in below expectations4
MoVincerx Pharma, Inc.: Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 202456VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors VIP943 pharmacokinetic...
► Artikel lesen
MoVincerx Pharma, Inc. - 8-K, Current Report1
05.04.Check-Cap, Outset Medical, Vincerx Pharma among healthcare movers6
01.04.Vincerx Pharma GAAP EPS of -$0.23 beats by $0.061
29.03.Vincerx Pharma Inc reports results for the quarter ended in December - Earnings Summary1
29.03.Vincerx Pharma, Inc. - 8-K, Current Report1
29.03.Vincerx Pharma, Inc.: Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update176VIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management at a virtual investor event on April 8 at 2:00...
► Artikel lesen
29.03.Vincerx Pharma, Inc. - 10-K, Annual Report1
05.03.Vincerx Pharma, Inc.: Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 20247
16.01.Vincerx Pharma, Inc. - 8-K, Current Report4
08.01.Vincerx Pharma stock rises on positive efficacy data from lymphoma therapy5
08.01.Why Is Cancer Focused Penny Stock Vincerx Pharma Trading Higher Today?4
08.01.Vincerx Pharma climbs on positive data from early-stage cancer therapy trial2
07.01.Vincerx Pharma, Inc.: Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma251Investigators from the National Institutes of Health (NIH) report 2 partial responses (PR) in 3 peripheral T-cell lymphoma (PTCL) patients and 1 PR in 2 double-hit diffuse large b-cell lymphoma (DH-DLBCL)...
► Artikel lesen
10.12.23Vincerx Pharma, Inc.: Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023155Poster on VIP943, a novel CD123-targeted antibody-drug conjugate (ADC) from our VersAptx platform, showcases selectivity, activity, and safety of VIP943 Poster on VIP924, a first-in-class CXCR5-targeted...
► Artikel lesen
Seite:  Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1